Sport Merck KGaA cancels clinical cancer study with Bintrafusp Alfa - share loses significantly

16:06  20 january  2021
16:06  20 january  2021 Source:   finanzen.net

Paul Bettany wants to play Star Wars character Dryden Vos once again

  Paul Bettany wants to play Star Wars character Dryden Vos once again Paul Bettany has revealed that he would be keen to play his 'Solo: A Star Wars Story' character Dryden Vos in a TV series.The 49-year-old actor portrayed crime lord Dryden Vos in 'Solo: A Star Wars Story' and admits that he would be keen to play the character once more despite his alter-ego's death in the 2018 film.

Merck KGaA , Darmstadt, Germany. The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer . This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy. Actual Study Start Date

Darmstadt-based Merck KGaA has canceled a cancer study with the bifunctional immunotherapy Bintrafusp Alfa.

TORU YAMANAKA/AFP/Getty Images © Provided by Finanz.net TORU YAMANAKA / AFP / Getty Images

The use of Bintrafusp Alfa as a first-line therapy for patients with PD-L1-expressing advanced stage IV non-small cell lung cancer (NSCLC) was investigated After looking at all the data from the ongoing study, the Group's Independent Data Monitoring Committee recommended on Wednesday that the clinical study INTR @ PID Lung 037 be terminated. Merck followed suit. It is unlikely that the study will reach its primary endpoint for effectiveness, according to the DAX group.

World first melanoma success in Australia prompts new trial

  World first melanoma success in Australia prompts new trial A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer. Charles Hanna had exhausted all treatments for his cancer, but tumours in his upper abdomen have now vanished.His world-first case has prompted the Melanoma Institute to run a new clinical trial. © 9News A new trial is underway after a melanoma patient received positive results from a breast cancer drug. READ MORE: Skin checks decrease by almost 50 percent in Victoria thanks to COVID"I was getting sicker by the day," Mr Hanna said.

In preclinical studies , bintrafusp alfa has demonstrated antitumor activity both as monotherapy and in combination with chemotherapy. Based on its mechanism of action, bintrafusp alfa offers a potential targeted approach to addressing the underlying pathophysiology of difficult-to-treat cancers .

Merck , a leading science and technology company, today announced 25 abstracts will be presented - Primary efficacy and biomarker analyses from ongoing VISION study for first-in-class tepotinib† in "In addition, studies from our ongoing clinical trials in advanced lung cancer from two of our in-house

Bintrafusp Alfa is currently in clinical trials and has no worldwide approval for any indication. Merck is investigating bifunctional immunotherapy as a potential therapy for difficult-to-treat cancers.

Merck KGaA slipping - important cancer study canceled

After the end of an important cancer study for the hopeful Bintrafusp Alfa of the pharmaceutical company Merck KGaA, their shares collapsed on Wednesday. Most recently, they were at the bottom of the DAX with a minus of around three percent to 144.30 euros via ETRA. The Darmstadt-based company had previously announced that it would end a clinical study evaluating bintrafusp alfa as a first-line therapy for patients with a certain advanced non-small cell lung cancer (NSCLC).

The cancer immunotherapy bintrafusp alfa has so far been seen as an important bearer of hope in Merck's drug pipeline. At the beginning of 2019, the DAX group entered into an alliance with the British pharmaceutical company GlaxoSmithKline to further develop the therapy. The agent has not yet been approved for any indication.

Even after the price slide, the Merck shares are still trading close to their record high of just under 150 euros.

FRANKFURT (Dow Jones) / FRANKFURT (dpa-AFX Broker)

These royal marriages broke up .
The big void in the life of Ulla Kock am Brink (59), left by the "far too early death of my beloved father, is still painful to this day. He died four years ago." also my brother-in-law, "says the moderator to BUNTE. "At some point you learn to live with grief and longing. But the day Dad died, our whole family structure changed." Her lively voice falters. "Dad and my brother-in-law Peter were diagnosed with cancer. Dad had colon cancer, Peter had pancreatic cancer.

usr: 3
This is interesting!